Literature DB >> 1625201

Toxicity of the 1-methyl-4-phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium species in primary cultures of mouse astrocytes.

E Y Wu1, J W Langston, D A Di Monte.   

Abstract

The biochemical and toxic effects of the two monoamine oxidase-generated metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine were investigated using primary cultures of mouse astrocytes. After the addition of equimolar concentrations (25 microM) of these metabolites, namely 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) ion or 1-methyl-4-phenylpyridinium (MPP+) ion, similar levels of MPP+ accumulated within the astrocytes. Both MPDP+ and MPP+ caused cytotoxicity which was preceded by increased glucose utilization and lactate accumulation. The metabolites were equipotent in producing a rapid decrease in cellular ATP which correlated well with the intracellular accumulation of MPP+ and the loss of cell viability. When astrocytes were incubated in glucose-free medium, both ATP depletion and loss of viability occurred more rapidly. Formation of MPP+ from MPDP+ was not affected by the presence of astrocytes, because MPP+ concentrations increased over time at the same rate regardless of the presence or absence of cells. In contrast to pretreatment of cells with monoamine oxidase inhibitors before addition of MPTP, pretreatment of astrocytes with deprenyl and clorgyline had no effect on intracellular levels of MPP+ after exposure to MPDP+ or MPP+ and did not protect against ATP depletion or cytotoxicity. These results indicate that 1) MPP+ and MPDP+ cause similar metabolic changes leading to cell death probably via ATP depletion; (2) intracellular levels of MPP+ are directly correlated to cytotoxicity; and (3) MPDP+ toxicity is also correlated to intracellular MPP+ accumulation, further confirming that MPP+ rather than MPDP+ is responsible for cell damage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1625201

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

2.  Increased extracellular glutamate evoked by 1-methyl-4-phenylpyridinium [MPP(+)] in the rat striatum is not essential for dopaminergic neurotoxicity and is not derived from released glutathione.

Authors:  S B Foster; H Tang; K E Miller; G Dryhurst
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

3.  Topological and chronological features of the impairment of glucose metabolism induced by 1-methyl-4-phenylpyridinium ion (MPP+) in rat brain slices.

Authors:  N Maruoka; T Murata; N Omata; Y Takashima; Y Fujibayashi; Y Wada
Journal:  J Neural Transm (Vienna)       Date:  2007-04-16       Impact factor: 3.575

Review 4.  Mitochondrial control of cell bioenergetics in Parkinson's disease.

Authors:  Raquel Requejo-Aguilar; Juan P Bolaños
Journal:  Free Radic Biol Med       Date:  2016-04-16       Impact factor: 7.376

5.  Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease.

Authors:  Sara Cipriani; Cody A Desjardins; Thomas C Burdett; Yuehang Xu; Kui Xu; Michael A Schwarzschild
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

6.  Anaerobic glycolysis protection against 1-methy-4-phenylpyridinium (MPP+) toxicity in C6 glioma cells.

Authors:  Zakia R Williams; Carl B Goodman; Karam F A Soliman
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 4.414

7.  Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP+ by Transporter-Independent Export of the Intermediate MPDP+.

Authors:  Stefan Schildknecht; Regina Pape; Johannes Meiser; Christiaan Karreman; Tobias Strittmatter; Meike Odermatt; Erica Cirri; Anke Friemel; Markus Ringwald; Noemi Pasquarelli; Boris Ferger; Thomas Brunner; Andreas Marx; Heiko M Möller; Karsten Hiller; Marcel Leist
Journal:  Antioxid Redox Signal       Date:  2015-11-01       Impact factor: 8.401

8.  Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model.

Authors:  Atsushi Fujita; Hiroo Yamaguchi; Ryo Yamasaki; Yiwen Cui; Yuta Matsuoka; Ken-Ichi Yamada; Jun-Ichi Kira
Journal:  J Neuroinflammation       Date:  2018-08-13       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.